Monthly information on share capital and company voting rights
Cellectis (CLLS) has reported its monthly share capital and voting rights information as of July 31, 2025. The company disclosed a total of 100,325,229 shares in its capital structure and 89,428,630 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth.
Cellectis (CLLS) ha comunicato le informazioni mensili relative al capitale sociale e ai diritti di voto al 31 luglio 2025. La società ha dichiarato un totale di 100.325.229 azioni nella sua struttura del capitale e 89.428.630 diritti di voto complessivi. Questa comunicazione è effettuata in conformità all'Articolo 223-16 del Regolamento Generale dell'autorità francese dei mercati finanziari, in relazione alla sua quotazione su Euronext Growth.
Cellectis (CLLS) ha informado sobre su capital social y derechos de voto mensuales al 31 de julio de 2025. La empresa declaró un total de 100.325.229 acciones en su estructura de capital y 89.428.630 derechos de voto totales. Esta divulgación se realiza de acuerdo con el Artículo 223-16 del Reglamento General de la autoridad financiera francesa para su cotización en Euronext Growth.
Cellectis (CLLS)는 2025년 7월 31일 기준 월간 주식 자본 및 의결권 정보를 보고했습니다. 회사는 자본 구조 내에 총 100,325,229주와 총 89,428,630개의 의결권을 공개했습니다. 이 공시는 Euronext Growth 상장을 위한 프랑스 금융시장 당국 일반 규정 제223-16조에 따라 이루어졌습니다.
Cellectis (CLLS) a publié ses informations mensuelles sur le capital social et les droits de vote au 31 juillet 2025. La société a déclaré un total de 100 325 229 actions dans sa structure de capital et 89 428 630 droits de vote totaux. Cette divulgation est effectuée conformément à l'article 223-16 du Règlement Général de l'autorité française des marchés financiers pour sa cotation sur Euronext Growth.
Cellectis (CLLS) hat seine monatlichen Angaben zum Aktienkapital und den Stimmrechten zum 31. Juli 2025 gemeldet. Das Unternehmen gab insgesamt 100.325.229 Aktien in seiner Kapitalstruktur und 89.428.630 Gesamtstimmrechte bekannt. Diese Offenlegung erfolgt gemäß Artikel 223-16 der Allgemeinen Verordnung der französischen Finanzmarktaufsichtsbehörde im Rahmen der Notierung an Euronext Growth.
- None.
- None.
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 07/31/2025 | 100,325,229 | 89,428,630 |
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Investor Relation contacts:
Arthur Stril, Chief Financial Officer & Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
What is the total number of shares outstanding for Cellectis (CLLS) as of July 31, 2025?
How many voting rights does Cellectis (CLLS) have as of July 2025?
Why is there a difference between Cellectis (CLLS) total shares and voting rights?
On which exchange is Cellectis (CLLS) stock listed?
